Skip to main content

Table 3 Western blotting results for RAC1, homer 1, APP, STEP, NSE, and β-actin and their ratios in BA9 a

From: Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex

 

Control

Autistic

Change

P-value

Cohen’s d

Adults

     

RAC1/β-actin

0.834 ± 0.554

1.66 ± 0.65

99%↑

0.031b

1.32b

Homer 1/β-actin

0.512 ± 0.152

0.324± 0.132

37%↓

0.027b

−1.37b

APP 120 kDa/β-actin

0.41 ± 0.23

0.45 ± 0.24

9.8%↑

ns

0.17

APP 88 kDa/β-actin

0.46 ± 0.19

0.53 ± 0.24

15%↑

ns

0.29

STEP 66 kDa/β-actin

0.10 ± 0.07

0.09 ± 0.08

10%↓

ns

−0.11

STEP 61 kDa/β-actin

0.73 ± 0.17

0.74 ± 0.18

1.3%↑

ns

0.08

STEP 46 kDa/β-actin

0.0097 ± 0.006

0.035 ± 0.031

261%↑

0.012b

1.10

STEP 33 kDa/β-actin

0.20 ± 0.13

0.18 ± 0.09

10%↓

ns

−0.25

STEP 27 kDa/β-actin

0.20 ± 0.12

0.16 ± 0.12

20%↓

ns

−0.29

β-actin

13.2 ± 2.41

13.1 ± 2.31

0.75%↓

ns

nd

Children

     

RAC1/β-actin

1 ± 0.616

2.8 ± 0.7

180%↑

0.008b

2.74b

Homer 1/β-actin

0.46 ± 0.17

0.77 ± 0.31

67%↑

ns

1.21

APP 120 kDa/β-actin

0.20 ± 0.07

0.63 ± 0.25

215%↑

0.032b

2.03b

APP 88 kDa/β-actin

0.22 ± 0.03

0.75 ± 0.26

241%↑

0.025b

2.54b

STEP 66 kDa/β-actin

0.027 ± 0.026

0.043 ± 0.031

59%↑

ns

0.54

STEP 61 kDa/β-actin

0.59 ± 0.22

0.29 ± 0.24

51%↓

0.036b

−1.23b

STEP 46 kDa/β-actin

0.008 ± 0.006

0.013 ± 0.014

62%↑

ns

0.45

STEP 33 kDa/β-actin

0.017 ± 0.026

0.033 ± 0.023

94%↑

ns

0.64

STEP 27 kDa/β-actin

0.17 ± 0.17

0.23 ± 0.10

35%↑

ns

0.45

β-actin

11.5 ± 1.31

11.7 ± 2.05

1.7%↑

ns

nd

Adults

     

RAC1/NSE

0.50 ± 0.33

0.95 ± 0.37

90%↑

0.042b

1.24

Homer 1/NSE

0.34 ± 0.12

0.19 ± 0.10

44%↓

0.020b

−1.43

APP 120 kDa/NSE

0.25 ± 0.12

0.27 ± 0.16

8%↑

ns

0.16

APP 88 kDa/NSE

0.28 ± 0.07

0.32 ± 0.14

14%↑

ns

0.27

STEP 66 kDa/NSE

0.17 ± 0.13

0.14 ± 0.12

18%↓

ns

−0.35

STEP 61 kDa/NSE

1.3 ± 0.34

1.18 ± 0.33

9.2%↓

ns

−0.25

STEP 46 kDa/NSE

0.017 ± 0.011

0.048 ± 0.041

182%↑

0.020b

1.02b

STEP 33 kDa/NSE

0.35 ± 0.20

0.28 ± 0.14

20%↓

ns

−0.46

STEP 27 kDa/NSE

0.35 ± 0.21

0.25 ± 0.17

29%↓

ns

−0.53

NSE

9.14 ± 3.73

8.59 ± 1.41

6%↓

ns

nd

Children

     

RAC1/NSE

0.61 ± 0.42

1.33 ± 0.21

118%↑

0.017b

2.09b

Homer 1/NSE

0.28 ± 0.11

0.40 ± 0.15

43%↑

ns

0.94

APP 120 kDa/NSE

0.12 ± 0.04

0.33 ± 0.12

175%↑

0.017b

2.12b

APP 88 kDa/NSE

0.13 ± 0.004

0.39 ± 0.11

200%↑

0.012b

3.24b

STEP 66 kDa/NSE

0.072 ± 0.081

0.097 ± 0.072

34%↑

ns

0.33

STEP 61 kDa/NSE

1.03 ± 0.25

0.69 ± 0.60

33%↓

ns

−0.68

STEP 46 kDa/NSE

0.021 ± 0.021

0.030 ± 0.033

43%↑

ns

0.37

STEP 33 kDa/NSE

0.050 ± 0.083

0.075 ± 0.054

50%↑

ns

0.37

STEP 27 kDa/NSE

0.49 ± 0.57

0.50 ± 0.26

2%↑

ns

0.031

NSE

6.58 ± 2.48

5.63 ± 1.3

14%↓

ns

nd

  1. Values for control and autistic groups are presented as mean ± SD.aRAC1, ras-related C3 botulinum toxin substrate 1; APP, amyloid beta A4 precursor protein; STEP, striatal-enriched protein tyrosine phosphatase; NSE, neuronal specific enolase; BA9, Brodmann’s area 9; nd, not determined; ns, not significant. bStatistically significant.